Biofourmis
Danny Plooster has a diverse work experience in various roles and industries. Danny started their career in 2012 as a Project Manager at Epic, where they worked until 2013. In 2016, they had a summer role as a Consultant at The Chartis Group. From 2017 to 2022, Danny worked at The Chartis Group, initially as a Consultant and later as an Engagement Manager. In 2022, they joined McKinsey & Company as a Client Development professional in the healthcare sector. Currently, Danny is working at Biofourmis as a Director of Customer Success, starting in 2023.
Danny Plooster has a Master of Business Administration (MBA) degree with a specialization in Carlson Consulting Enterprise and Medical Industry from the University of Minnesota, which they completed from 2015 to 2017. Danny also holds a Master of Healthcare Administration (MHA) degree from the same university, completed from 2014 to 2017. Prior to that, they obtained a Bachelor of Business Administration (B.B.A.) degree from the University of Wisconsin-Madison, specializing in Finance, Investment and Banking, as well as MHR Management, completed from 2007 to 2012. In addition, they studied Management and Economics at Università Bocconi in 2010.
This person is not in any offices
Biofourmis
6 followers
Biofourmis is a fast-growing digital health company filled with committed, passionate people who care about augmenting personalized care and empowering people with complex chronic conditions to live better and healthier lives. They are pioneering an entirely new category of medicine, by developing clinically validated software-based therapeutics to provide better outcomes for patients, smarter engagement and tracking tools for clinicians, and cost-effective solutions for payers. Biofourmis has built Biovitals®, a highly sophisticated personalized AI-powered health analytics platform that predicts clinical exacerbation in advance of a critical event, which is the backbone of their digital therapeutics’ product pipeline across multiple therapeutic areas—including heart failure, oncology, acute coronary syndrome, COPD and chronic pain.